검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Larotrectinib |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Advanced Lymphoma; Advanced Malignant Solid Neoplasm |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target mutations or new pathway |
MoA Biomarker | biomarker-guided combination strategy to overcome lenvatinib resistance in HCC |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma.. Resistance to lenvatinib remains a major barrier in the treatment of advanced hepatocellular carcinoma (HCC), underscoring the urgent need to elucidate the underlying mechanisms and identify actionable therapeutic targets. In this study, we identified a neurosecretory factor derived from HCC… |
Clinical Primary efficacy | ORR 94.4% |
Clinical ORR | 94.4% |
Clinical OS | 100 |
Clinical Result source | ClinicalTrials.gov NCT03834961 |
Clinical Data Tier / Score | A · 63 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Larotrectinib |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Advanced Lymphoma; Advanced Malignant Solid Neoplasm |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target mutations or new pathway |
MoA Biomarker | biomarker-guided combination strategy to overcome lenvatinib resistance in HCC |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma.. Resistance to lenvatinib remains a major barrier in the treatment of advanced hepatocellular carcinoma (HCC), underscoring the urgent need to elucidate the underlying mechanisms and identify actionable therapeutic targets. In this study, we identified a neurosecretory factor derived from HCC… |
Clinical Primary efficacy | ORR 94.4% |
Clinical ORR | 94.4% |
Clinical OS | 100 |
Clinical Result source | ClinicalTrials.gov NCT03834961 |
Clinical Data Tier / Score | A · 63 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교